Perform proteomic profiling comparing triple-negative apocrine carcinoma (TNAC) and luminal androgen receptor-type triple-negative breast cancer (LAR-TNBC) to elucidate their molecular distinctions and validate TNAC as a distinct entity separate from LAR-TNBC.